Harvard Apparatus Regenerative Technology, Inc. 8-K

What Happened

• On April 27, 2026, Harvard Apparatus Regenerative Technology, Inc. issued a press release announcing that the first patient has been treated with the Company’s Cellspan™ Esophageal Implant (CEI) in its Phase 1 feasibility and safety clinical trial at the Mayo Clinic in Rochester, Minnesota.
• The company furnished the press release as Exhibit 99.1 to its Form 8-K filed on April 28, 2026 under Item 7.01 (Regulation FD Disclosure).

Key Details

• Date of announcement: April 27, 2026 (Form 8-K filed April 28, 2026).
• Product: Cellspan™ Esophageal Implant (CEI).
• Trial: Phase 1 feasibility and safety clinical trial being conducted at the Mayo Clinic, Rochester, MN.
• Disclosure type: Regulation FD press release furnished as Exhibit 99.1.

Why It Matters

• This is an early clinical milestone: first patient treatment in a Phase 1 trial is a key step in clinical development and may reduce near-term clinical execution risk if the program continues as planned.
• The filing contains no financial results or timelines for next clinical or regulatory milestones; investors should view this as operational progress rather than a guarantee of future outcomes.
• As a Regulation FD disclosure, the announcement ensures broad, equal public access to the development — relevant for investors tracking clinical and regulatory news for the company.